Edition:
India

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.32USD
1:08am IST
Change (% chg)

$0.03 (+0.70%)
Prev Close
$4.29
Open
$4.26
Day's High
$4.34
Day's Low
$4.17
Volume
77,490
Avg. Vol
210,893
52-wk High
$7.53
52-wk Low
$3.64

Chart for

About

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery... (more)

Overall

Beta: 2.96
Market Cap(Mil.): $600.01
Shares Outstanding(Mil.): 90.23
Dividend: --
Yield (%): --

Financials

BRIEF-Inovio Pharmaceuticals Q1 Loss Per Share $0.36

* INOVIO PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

10 May 2018

BRIEF-Inovio Pharmaceuticals Says For Qtr Ended March 31, Net Loss Per Share Was $0.36

* INOVIO PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, NET LOSS PER SHARE WAS $0.36 - SEC FILING

10 May 2018

BRIEF-Inovio Awarded Up To $56 Million From Cepi To Advance Dna Vaccines Against Lassa Fever And Mers

* INOVIO AWARDED UP TO $56 MILLION FROM CEPI TO ADVANCE DNA VACCINES AGAINST LASSA FEVER AND MERS

11 Apr 2018

BRIEF-Inovio Closes License And Collaboration Agreement With ApolloBio To Develop And Commercialize VGX-3100 In Greater China

* INOVIO CLOSES LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

20 Mar 2018

BRIEF-Inovio Pharmaceuticals Reports Qtrly ‍Net Loss Attributable To Stockholders Of $0.24 Per Basic Share​

* INOVIO PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

15 Mar 2018

BRIEF-Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key In Treating Chronic Hepatitis B Infection

* INOVIO'S DNA IMMUNOTHERAPY DEMONSTRATES IMMUNE RESPONSE RESULTS KEY IN TREATING CHRONIC HEPATITIS B INFECTION Source text for Eikon: Further company coverage:

14 Mar 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.00 -1.80
Novartis AG (NOVN.S) CHF80.96 +0.30
Pfizer Inc. (PFE.N) $37.40 -0.26
Merck & Co., Inc. (MRK.N) $62.56 -0.38
Sanofi SA (SASY.PA) €72.11 -0.40
GlaxoSmithKline plc (GSK.L) 1,558.00 -5.80
AstraZeneca plc (AZN.L) 5,609.00 +3.00

Earnings vs. Estimates